Document Type


Journal Title

Cancer biotherapy & radiopharmaceuticals

Publication Date

Fall 10-7-2013




Due to its ability to target both known and occult lesions, radioimmunotherapy (RIT) is an attractive therapeutic modality for solid tumors. Poor tumor uptake and undesirable pharmacokinetics, however, have precluded the administration of radioimmunoconjugates at therapeutically relevant doses thereby limiting the clinical utility of RIT. In solid tumors, efficacy of RIT is further compromised by heterogeneities in blood flow, tumor stroma, expression of target antigens and radioresistance. As a result significant efforts have been invested toward developing strategies to overcome these impediments. Further, there is an emerging interest in exploiting short-range, high energy α-particle emitting radionuclides for the eradication of minimal residual and micrometastatic disease. As a result several modalities for localized therapy and models of minimal disease have been developed for preclinical evaluation. This review provides a brief update on the recent efforts toward improving the efficacy of RIT for solid tumors, and development of RIT strategies for minimal disease associated with solid tumors. Further, some of promising approaches to improve tumor targeting, which showed promise in the past, but have now been ignored are also discussed.

MeSH Headings

Alpha Particles, Animals, Antibodies, Monoclonal, Disease Models, Animal, Humans, Immunoconjugates, Neoplasm, Residual, Neoplasms, Peritoneum, Radioimmunotherapy, Radioisotopes, Radiopharmaceuticals




This is a copy of an article published in the Cancer Biotherapy and Radiopharmaceuticals© 2013 [copyright Mary Ann Liebert, Inc.]; Cancer Biotherapy and Radiopharmaceuticals is available online at: